Skip to Content
Authors Zhou L, Wei X, Cheng L, Tian J, Jiang JJ
Author Profile(s)
Journal Laryngoscope Volume: 117 Issue: 3 Pages: 455-60
Publish Date 2007 Mar
PubMed ID 17334305

In recent years, a growing body of evidence has been reported that a tumor clone is organized as a hierarchy that originates from rare stem cells. CD133, a cell surface antigen, was identified as a stem cell maker for human leukemia, brain tumors, and prostate cancer. The purpose of this study was to detect the expression of CD133, a putative marker of cancer stem cells in the Hep-2 cell line, and isolate CD133 positive cells to observe their proliferation and differentiation ability in vitro.Immunocytochemical staining technology and flow cytometry were used to detect the expression of the putative stem cell marker CD133 in a Hep-2 cell line. The immunomagnetic beads were applied to purify CD133 positive cells. CD133+ tumor cells were cultured in vitro to observe their ability to proliferate and differentiate.Only a small proportion (<5%) of cells in the Hep-2 cell line expressed CD133. CD133+ cells possess a marked capacity for self renewal, extensive proliferation, and mutilineal differentiation potency in vitro.CD133 is one of the markers for cancer stem cells in human laryngeal tumors, the Hep-2 cell line. Copyright © 2017 The Board of Regents of the University of Wisconsin System